Phase II study of a PARP inhibitor, talazoparib, in HER2-metastatic breast cancer (MBC) with a somatic BRCA1/2mutation identified in a cell-free DNA or tumor tissue genotyping assay

被引：0
|
作者：
Vidula, Neelima
Damodaran, Senthil
Bhave, Manali A.
Blouch, Erica
Ogbenna, Ogadinma
Flaum, Lisa E.
Shah, Ami N.
Abramson, Vandana G.
Cristofanilli, Massimo
Sparano, Joseph A.
Ostrer, Harry
Horick, Nora K.
Rugo, Hope S.
Bardia, Aditya
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[3] Emory Univ, Sch Med, Atlanta, GA USA
[4] Massachusetts Gen Hosp, Boston, MA USA
[5] Northwestern Med Grp, Chicago, IL USA
[6] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[7] Vanderbilt Univ, Nashville, TN USA
[8] Weill Cornell Med, New York, NY USA
[9] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA
[10] Albert Einstein Coll Med, Bronx, NY USA
[11] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[12] UCLA, Hlth Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1143
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II study of a PARP inhibitor, talazoparib, in HER2-metastatic breast cancer with a somatic BRCA1/2 mutation present in cell-free DNA or tumor tissue genotyping
    Vidula, Neelima
    Damodaran, Senthil
    Bhave, Manali
    Rugo, Hope
    Shah, Ami N.
    Blouch, Erica
    Ruffle-Deignan, Nathan Royce
    Ogbenna, Ogadinma
    Flaum, Lisa E.
    Cristofanilli, Massimo
    Sparano, Joseph
    Ostrer, Harry
    Abramson, Vandana
    Horick, Nora
    Bardia, Aditya
    CANCER RESEARCH, 2024, 84 (09)
  • [2] Phase II study of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer identified by cell-free DNA or tumor tissue genotyping
    Vidula, Neelima
    Damodaran, Senthil
    Blouch, Erica L.
    Horick, Nora
    Ruffle-Deignan, Nathan Royce
    Bhave, Manali
    Shah, Ami N.
    Varella, Leticia
    Abramson, Vandana
    Sparano, Joseph
    Ellisen, Leif
    Alim, Ishraq
    Ostrer, Harry
    Rugo, Hope
    Bardia, Aditya
    CANCER RESEARCH, 2023, 83 (05)
  • [3] Phase II study of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer
    Vidula, Neelima
    Horick, Nora
    Basile, Erin
    Blouch, Erica
    Ellisen, Leif W.
    Rugo, Hope S.
    Bardia, Aditya
    CANCER RESEARCH, 2021, 81 (04)
  • [4] Phase II study of a PARP inhibitor in somatic BRCA1/2 mutant metastatic breast cancer (MBC)
    Vidula, Neelima
    Damodaran, Senthil
    Bhave, Manali A.
    Rugo, Hope S.
    Blouch, Erica
    Ruffle-Deignan, Nathan Royce
    Shah, Ami N.
    Cristofanilli, Massimo
    Abramson, Vandana G.
    Sparano, Joseph A.
    Ostrer, Harry
    Horick, Nora K.
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Phase II multicenter study of talazoparib for somatic BRCA1/2 mutant metastatic breast cancer.
    Vidula, Neelima
    Blouch, Erica
    Horick, Nora K.
    Basile, Erin
    Damodaran, Senthil
    Liu, Minetta C.
    Shah, Ami N.
    Moreno-Aspitia, Alvaro
    Rugo, Hope S.
    Ellisen, Leif
    Bardi, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Phase II study of a PARP inhibitor in metastatic breast cancer with somaticBRCA1/2mutations identified by cell-free DNA: Genotyping based clinical trial
    Vidula, Neelima
    Blouch, Erica
    Basile, Erin
    Ruffle-Deignan, Nathan Royce
    Horick, Nora
    Damodaran, Senthil
    Aspitia, Alvaro Moreno
    Bhave, Manali
    Shah, Ami
    Liu, Minetta C.
    Sparano, Joseph
    Ostrer, Harry
    Rugo, Hope
    Ellisen, Leif W.
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [7] Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, aberrations in other BRCA pathway genes, and germline mutations in BRCA1/2 (not breast or ovarian cancer)
    Piha-Paul, Sarina A.
    Xiong, Wendy Wen
    Moss, Tyler
    Mostorino, Rosa M.
    Sedelmeier, Shelby
    Hess, Kenneth
    Fu, Siqing
    Hong, David
    Janku, Filip
    Karp, Daniel
    Naing, Aung
    Pant, Shubham
    Rodon, Jordi
    Subbiah, Vivek
    Tsimberidou, A. M.
    Yap, Timothy
    Javle, Milind
    Tapia, Coya
    Shaw, Kenna R.
    Eterovic, Karina
    Mills, Gordon B.
    Meric-Bernstam, Funda
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [8] PARP Inhibitor for advanced BRCA1/2 Breast Cancer Talazoparib: Prolonging progression-free Survival without Chemotherapy
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (7-8) : 397 - 397
  • [9] Phase IV study evaluating effectiveness and safety of talazoparib in patients with locally advanced or metastatic HER2 negative breast cancer and a BRCA1 or BRCA2 mutation (ViTAL)
    Loirat, Delphine
    de labarre, Marie Duboys
    Essner, Christine
    Hrab, Ioana
    Thery, Jean-Christophe
    Jouannaud, Christelle
    Vuagnat, Perrine
    Soibinet-Oudot, Pauline
    Creisson, Anne
    Mailliez, Audrey
    Mouysset, Jean-Loup
    Salabert, Laura
    Dohollou, Nadine
    Fumet, Jean-David
    Rouge, Thibault De La Motte
    Vauthier, Jean-Michel
    Decrop, Maylis
    Pujol, Pascal
    CANCER RESEARCH, 2022, 82 (04)
  • [10] Phase II study of the PARP inhibitor talazoparib (BMN-673) in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, a homologous recombination defect, mutations/deletions in other BRCA pathway genes and germline mutation S in BRCA1/2 (not breast or ovarian cancer).
    Piha-Paul, Sarina Anne
    Goldstein, Jennifer Brooke
    Hess, Kenneth R.
    Fu, Siqing
    Hong, David S.
    Janku, Filip
    Karp, Daniel D.
    Naing, Aung
    Subbiah, Vivek
    Tsimberidou, Apostolia Maria
    Wheler, Jennifer J.
    Zinner, Ralph
    Mills, Gordon B.
    Meric-Bernstam, Funda
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345